Jiangsu Aidea Pharmaceutical Co Ltd Net Asset Quality Index
Jiangsu Aidea Pharmaceutical Co Ltd net asset quality index. Jiangsu Aidea Pharmaceutical Co Ltd (688488) has a Net Asset Quality Index of 49.3% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.98 Billion minus total liabilities of CN¥1.00 Billion yields net assets of CN¥974.37 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Jiangsu Aidea Pharmaceutical Co Ltd (688488) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Jiangsu Aidea Pharmaceutical Co Ltd (2016–2025)
Net asset quality index of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025. This chart shows how Jiangsu Aidea Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 10 annual periods from 2016 to 2025. As of June 2026, the index stands at 49.3%, representing net assets of CN¥974.37 Million against total assets of CN¥1.98 Billion CNY. See Jiangsu Aidea Pharmaceutical Co Ltd net assets for net asset value and shareholders' equity analysis.
Jiangsu Aidea Pharmaceutical Co Ltd Net Asset Quality Index by Year (2016–2025)
Jiangsu Aidea Pharmaceutical Co Ltd net asset quality index by year from 2016 to 2025. The table below presents the year-by-year Net Asset Quality Index for Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025, covering 10 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Jiangsu Aidea Pharmaceutical Co Ltd market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 56.1% | CN¥1.07 Billion | CN¥1.91 Billion | CN¥839.37 Million | ▼ -1.0 pp |
| 2024 | 57.1% | CN¥1.07 Billion | CN¥1.87 Billion | CN¥802.48 Million | ▼ -7.4 pp |
| 2023 | 64.4% | CN¥1.13 Billion | CN¥1.75 Billion | CN¥621.03 Million | ▼ -8.0 pp |
| 2022 | 72.4% | CN¥1.20 Billion | CN¥1.66 Billion | CN¥456.23 Million | ▼ -18.9 pp |
| 2021 | 91.3% | CN¥1.31 Billion | CN¥1.43 Billion | CN¥124.82 Million | ▼ -2.7 pp |
| 2020 | 94.0% | CN¥1.36 Billion | CN¥1.45 Billion | CN¥86.97 Million | ▲ +22.8 pp |
| 2019 | 71.2% | CN¥556.24 Million | CN¥780.98 Million | CN¥224.74 Million | ▼ -2.5 pp |
| 2018 | 73.7% | CN¥522.71 Million | CN¥708.95 Million | CN¥186.24 Million | ▼ -4.3 pp |
| 2017 | 78.0% | CN¥514.09 Million | CN¥659.24 Million | CN¥145.14 Million | ▲ +10.3 pp |
| 2016 | 67.7% | CN¥300.40 Million | CN¥443.55 Million | CN¥143.16 Million | — |